YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: combination nivolumab and ipilimumab

First Posted Date: 2017-08-25

Last Posted Date: 2025-01-09

Lead Sponsor: Yale University

Target Recruit Count: 20

Registration Number: NCT03262779

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Diabetes Prevention With Lifestyle Intervention and Metformin Escalation

Phase 4

Terminated

Conditions: Diabetes

Interventions: Behavioral: Lifestyle Intervention
Drug: Metformin

First Posted Date: 2017-08-23

Last Posted Date: 2024-02-06

Lead Sponsor: Yale University

Target Recruit Count: 114

Registration Number: NCT03258723

Locations: 🇻🇮
Ministry of Health Clinics, Charlotte Amalie, Virgin Islands (U.S.)
🇹🇹
Southwest Regional Health Authority, La Romaine Health Center, San Fernando, Trinidad and Tobago
🇧🇧
University of the West Indies, Cavehill and Barbados Ministry of Health Polyclinics, Bridgetown, Barbados

and more 1 locations

Glucocorticoid Antagonist Treatment for Tobacco Use Disorder

Early Phase 1

Terminated

Conditions: Nicotine Dependence

Interventions: Drug: Placebo
Drug: Mifepristone

First Posted Date: 2017-08-14

Last Posted Date: 2019-05-28

Lead Sponsor: Yale University

Target Recruit Count: 8

Registration Number: NCT03248713

Locations: 🇺🇸
Veterans Affairs Hospital, West Haven, Connecticut, United States

Readiness to Disclose Mother's HIV Diagnosis to Their Children in Beijing, China

Not Applicable

Completed

Conditions: HIV

Interventions: Behavioral: disclosure-support counseling intervention

First Posted Date: 2017-08-14

Last Posted Date: 2019-07-08

Lead Sponsor: Yale University

Target Recruit Count: 5

Registration Number: NCT03248778

Locations: 🇨🇳
Beijing Ditan Hospital, Beijing, China

Effects of Flavors on Nicotine Reinforcement in Smokers

Early Phase 1

Completed

Conditions: Nicotine Dependence

Interventions: Drug: IV nicotine
Drug: Menthol flavor
Drug: green apple
Drug: green apple and menthol

First Posted Date: 2017-08-09

Last Posted Date: 2020-12-03

Lead Sponsor: Yale University

Target Recruit Count: 26

Registration Number: NCT03243630

Locations: 🇺🇸
Veterans Affairs, West Haven, Connecticut, United States

Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy

Phase 1

Completed

Conditions: Post-Prandial Hyperglycemia
Post-Prandial Hypoglycemia

Interventions: Device: DiAS
Drug: Afrezza low dose
Drug: Afrezza high dose

First Posted Date: 2017-07-31

Last Posted Date: 2022-05-25

Lead Sponsor: Yale University

Target Recruit Count: 15

Registration Number: NCT03234491

Locations: 🇺🇸
Yale Diabetes Research Clinic, New Haven, Connecticut, United States

Yale Wellness Project

Not Applicable

Completed

Conditions: Mental Health Wellness 1

Interventions: Behavioral: Emotional Intelligence
Behavioral: Mindfulness-Based Stress Reduction
Behavioral: Sudarshan Kriya Yoga

First Posted Date: 2017-07-25

Last Posted Date: 2020-03-13

Lead Sponsor: Yale University

Target Recruit Count: 300

Registration Number: NCT03229577

Locations: 🇺🇸
Yale Center for Emotional Intelligence, New Haven, Connecticut, United States

Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

Phase 1

Terminated

Conditions: Delta-9-Tetrahydroncannabinol
Bipolar Disorder
Healthy Controls

Interventions: Drug: Placebo
Drug: 4 mg Delta-9-THC
Drug: 2 mg Delta-9-THC

First Posted Date: 2017-07-02

Last Posted Date: 2022-01-31

Lead Sponsor: Yale University

Target Recruit Count: 2

Registration Number: NCT03206463

Locations: 🇺🇸
Biological Studies Unit, VA Connecticut Healthcare System, West Haven, Connecticut, United States

Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes

Completed

Conditions: IGT - Impaired Glucose Tolerance
T2D

Interventions: Diagnostic Test: Oral Glucose Tolerance Test
Diagnostic Test: Hyperglycemic Clamp
Diagnostic Test: Isoglycemic Intravenous Glucose Test
Diagnostic Test: Hyperinsulinemic Euglycemic Clamp and 2H20

First Posted Date: 2017-06-22

Last Posted Date: 2023-02-23

Lead Sponsor: Yale University

Target Recruit Count: 100

Registration Number: NCT03195400

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Sugammadex and Decreased Time to Extubation

Phase 4

Completed

Conditions: Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery

Interventions: Other: Placebo
Drug: Sugammadex

First Posted Date: 2017-06-22

Last Posted Date: 2022-01-14

Lead Sponsor: Yale University

Target Recruit Count: 90

Registration Number: NCT03196167

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy